Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Taysha Gene Therapies stock | 21.8

Own Taysha Gene Therapies stock in just a few minutes.

Updated . What changed?

Fact checked

Taysha Gene Therapies, Inc. is a biotechnology business based in the US. Taysha Gene Therapies shares (TSHA) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Taysha Gene Therapies

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Taysha Gene Therapies. Find the stock by name or ticker symbol: TSHA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Taysha Gene Therapies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$21.8, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Taysha Gene Therapies, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Taysha Gene Therapies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Taysha Gene Therapies share price

Use our graph to track the performance of TSHA stocks over time.

Taysha Gene Therapies shares at a glance

Information last updated 2020-10-19.
Latest market closeUSD$21.8
52-week rangeUSD$19.316 - USD$27.53
50-day moving average USD$21.5465
200-day moving average USD$21.5465
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks
N/A
0%
A free way to invest in stocks, ETFs and crypto.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Tastyworks
$0
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Taysha Gene Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Taysha Gene Therapies price performance over time

Historical closes compared with the close of $21.8 from 2020-10-16

1 week (2020-10-14) 1.96%
1 month (2020-09-18) N/A
3 months (2020-07-18) N/A
6 months (2020-04-18) N/A
1 year (2019-10-18) N/A
2 years (2018-10-18) N/A
3 years (2017-10-18) N/A
5 years (2015-10-18) N/A

Taysha Gene Therapies financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$814.9 million

TTM: trailing 12 months

Shorting Taysha Gene Therapies shares

There are currently 255,270 Taysha Gene Therapies shares held short by investors – that's known as Taysha Gene Therapies's "short interest". This figure is up from 0 last month.

There are a few different ways that this level of interest in shorting Taysha Gene Therapies shares can be evaluated.

Taysha Gene Therapies's "short interest ratio" (SIR)

Taysha Gene Therapies's "short interest ratio" (SIR) is the quantity of Taysha Gene Therapies shares currently shorted divided by the average quantity of Taysha Gene Therapies shares traded daily (recently around 945444.44444444). Taysha Gene Therapies's SIR currently stands at 0.27. In other words for every 100,000 Taysha Gene Therapies shares traded daily on the market, roughly 270 shares are currently held short.

To gain some more context, you can compare Taysha Gene Therapies's short interest ratio against those of similar companies.

However Taysha Gene Therapies's short interest can also be evaluated against the total number of Taysha Gene Therapies shares, or, against the total number of tradable Taysha Gene Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Taysha Gene Therapies's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Taysha Gene Therapies shares in existence, roughly 10 shares are currently held short) or 0.0147% of the tradable shares (for every 100,000 tradable Taysha Gene Therapies shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Taysha Gene Therapies.

Find out more about how you can short Taysha Gene Therapies stock.

Taysha Gene Therapies share dividends

We're not expecting Taysha Gene Therapies to pay a dividend over the next 12 months.

Taysha Gene Therapies overview

Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.

Frequently asked questions

More guides on finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site